CNBC’s Jim Cramer says money should flow from stocks with heavy exposure to Ukraine and China into domestic retailers with strong growth.» Read More
The first rule of insider trading: Don’t talk about insider trading—or do a lot of Internet searches about it.
Take a look at some of Thursday's midday movers:
FBI agents arrested Robert Ramnarine, a Bristol-Myers Squibb executive, on Thursday, and criminally charged him with insider trading in call options, court papers show.
Bristol-Myers Squibb suspended a mid-stage study of its experimental hepatitis C drug BMS-094 due to a serious safety issue — a major blow to the company’s research pipeline that is also likely to rejigger the way Wall Street views other companies’ efforts to develop an all-oral therapy against the viral liver disease.
Take a look at some of Wednesday's morning movers:
Generic competition will be the major headwind that Bristol-Myers Squibb faces this quarter, as its blockbuster drug Plavix — which saw U.S. sales peak at $7 billion last year — went off patent in May.
Dr. Leonard Schleifer, Regeneron Pharmaceuticals president & CEO, discusses competition in the pharma sector and upcoming clinical trials. "One of the things that's particularly exciting for a lot of people is our approach to lowering cholesterol," says Schleifer.
CNBC's Seema Mody discusses the details of the deal between pharma companies Bristol-Myers and Amylin.
CNBC's Scott Cohn reports on what the Justice Department calls the biggest health care fraud settlement in U.S. history; and CNBC's Seema Mody reports on the details of Bristol-Myers' plans to buy Amylin.
CNBC's David Faber reports the Dish Network and AMC contract expired without a new agreement, and a look at the deal between Bristol-Myers and Amylin Pharma.
U.S. stock index futures briefly edged higher Wednesday following a better-than-expected durable goods orders report, but quickly erased gains to turn mixed again as investors remained cautious ahead of another EU summit later this week.
Barbara Ryan, Deutsche Bank Securities senior pharmaceutical analyst, takes a look at the vital signs of big drug companies and weighs in on what to expect from the Supreme Court's ruling on President Obama's health care overhaul plan.
The "Squawk on the Street" team discusses the latest action in Facebook, Bristol-Myers and Eli Lilly.
Investors have made big bets on drugs like Pfizer's Lipitor for cholesterol, Glaxo's Advair for Asthma, and many more. CNBC's Seema Mody reports rare diseases might be the next hot investment.
Bristol-Myers' top selling blood thinner "Plavix" is going generic, reports CNBC's Seema Mody. Matt Cheslock, Virtu Financial, weighs in on how to trade the pharmaceuticals sector right now.
CNBC's Eamon Javers reports on Bristol-Meyers receiving a subpoena from the SEC. Also, Avon Group's Vice President Kerry Carr is resigning amid allegations of a bribery in China.
A breakdown of the drug-maker's Q4 profit after reporting a loss a year earlier, with Andrew Witty, GlaxoSmithKline CEO.
Mad Money's Jim Cramer, explains how big drug makers like, Pfizer and Bristol-Myers could pay off big time for investors.
Dr. Tony Coles, president & CEO of Onyx Pharmaceuticals, discusses his outlook on pharma in the new year. Biotech stocks were up 7% in 2011. "The emerging markets should be great for us," he adds.
Dendreon's revenues for its solo product, Provenge, has more than tripled from a year ago. Insight on the drug's treatment of prostate cancer and an outlook on the healthcare sector, with Mitchell Gold, Dendreon president/CEO.